Advancing Gastric Cancer Research: Assembloid Models Integrating Tumor Organoids and Stromal Cell Subpopulations

Study Background and Research Question

Gastric cancer remains a significant global health burden, ranking as the fifth most diagnosed malignancy and the second leading cause of cancer-related mortality worldwide. Despite advances in surgery, chemotherapy, targeted therapy, and immunotherapy, the five-year survival rate for advanced or metastatic gastric cancer remains below 10%. This poor outlook is attributed in large part to the marked heterogeneity of gastric tumors, which complicates treatment and contributes to variable drug responses. Traditional in vitro models, including organoids, have enhanced our ability to study tumor biology, but they often fail to replicate the full complexity of the tumor microenvironment—particularly the diversity of stromal cell populations that modulate cancer progression and therapeutic resistance. The central research question addressed by Shapira-Netanelov et al. (2025) is how to generate a preclinical model that more faithfully mirrors the heterogeneity and cell–cell interactions of human gastric tumors, thereby improving the predictive power for drug response and resistance mechanisms.

Key Innovation from the Reference Study

The principal innovation in this work is the development of a patient-derived gastric cancer assembloid model that integrates autologous tumor organoids with matched stromal cell subpopulations. Unlike conventional organoid cultures, which typically consist of isolated epithelial tumor cells, this assembloid system incorporates mesenchymal stem cells, fibroblasts, and endothelial cells—all derived from the same patient tumor tissue. This approach recreates the cellular heterogeneity and microenvironmental complexity characteristic of primary gastric tumors. The model allows detailed interrogation of tumor–stroma interactions, gene expression dynamics, and personalized drug responses, offering a robust platform for both mechanistic studies and translational assay development. By revealing how stromal cell subsets shape inflammatory signaling, extracellular matrix remodeling, and drug sensitivity, the assembloid model addresses a longstanding gap in preclinical cancer research (reference study).

Methods and Experimental Design Insights

The study leveraged a multi-step experimental process to generate the assembloid models:

• Tumor Tissue Dissociation and Expansion: Patient-derived gastric tumor specimens were enzymatically dissociated into single-cell suspensions. Distinct subpopulations were expanded using tailored culture conditions optimized for epithelial organoids, mesenchymal stem cells, fibroblasts, or endothelial cells.
• Co-culture Assembly: The purified cell types were recombined in an optimized assembloid medium that supports the growth and maintenance of all cellular components. This co-culture system was designed to maintain physiological ratios and promote cell–cell interactions.
• Characterization: Cellular identity and heterogeneity were confirmed by immunofluorescence staining for epithelial and stromal markers. Transcriptomic profiling via RNA sequencing provided a comprehensive view of gene expression patterns within the assembloids.
• Drug Response Assessment: The assembloids were subjected to cell viability and proliferation assays following exposure to multiple therapeutic agents, enabling comparison of drug sensitivity between monoculture organoids and assembloid systems.

This rigorous workflow ensured that the resulting assembloids closely recapitulated the architecture and signaling milieu of patient tumors, while providing a tractable platform for mechanistic and pharmacological studies.

Protocol Parameters

• Tumor dissociation: Enzymatic digestion to obtain single-cell suspensions from fresh gastric tumor tissue.
• Cell expansion: Use of lineage-specific growth media for epithelial organoids, mesenchymal stem cells, fibroblasts, and endothelial cells.
• Assembloid formation: Co-culture in an optimized medium, maintaining ratios reflective of the source tumor’s cellular composition.
• Characterization: Immunofluorescence for epithelial (e.g., EPCAM) and stromal (e.g., vimentin, αSMA) markers; transcriptomic profiling by RNA-seq.
• Drug screening: Application of cell viability and proliferation assays (e.g., MTT, CellTiter-Glo) following treatment with standard chemotherapeutics and targeted agents.

Core Findings and Why They Matter

The optimized co-culture assembloid system demonstrated several critical advances over prior models, as detailed in the reference study:

• Enhanced Cellular Heterogeneity: The assembloids faithfully reflected the diversity of primary gastric tumors, displaying robust expression of both epithelial and stromal markers.
• Gene Expression Dynamics: Compared to monocultures, assembloids exhibited elevated levels of inflammatory cytokines, extracellular matrix remodeling factors, and tumor progression-related genes, underscoring the influence of stromal cells on tumor biology.
• Drug Response Variability: Drug screening revealed that some agents were equally effective in organoid and assembloid models, while others lost efficacy in the presence of stromal components. This finding highlights the key role of the tumor microenvironment in mediating drug resistance and underscores the importance of physiologically relevant models for preclinical testing.
• Personalized Insights: The system supports individualized drug screening, enabling the identification of patient- and drug-specific response patterns and resistance mechanisms.

Collectively, these results demonstrate that assembloid models offer a powerful, customizable platform for dissecting tumor–stroma crosstalk and optimizing therapeutic strategies in gastric cancer.

Comparison with Existing Internal Articles

Several recent reviews and technical articles have explored the application of Leucovorin Calcium (calcium folinate) in translational cancer research, particularly in the context of methotrexate rescue and antifolate drug resistance. For example, one internal article discusses the mechanistic value of Leucovorin Calcium in advanced assembloid models, highlighting its role in sustaining cell viability and modeling resistance pathways. Another resource (Leucovorin Calcium in Tumor Assembloids) presents practical guidelines for integrating the compound into cell proliferation assays and modeling protection from methotrexate-induced growth suppression. These works complement the reference study by providing actionable insights into workflow optimization, solubility management, and the interpretation of cell proliferation data in complex co-culture systems.

The current reference paper advances the field by demonstrating the necessity of stromal cell inclusion for accurate assessment of drug efficacy and resistance mechanisms—an aspect directly relevant to antifolate drug resistance research and the use of folate analogs such as Leucovorin Calcium.

Limitations and Transferability

While the assembloid model represents a significant advance, certain limitations should be considered:

• Technical Complexity: The isolation and expansion of multiple autologous cell subpopulations require specialized expertise and resources not universally available in all research settings.
• Tumor Sample Availability: The approach depends on the availability of sufficient fresh tumor material from individual patients, which may not always be feasible.
• Transferability to Other Cancer Types: Although the system is optimized for gastric cancer, further validation is needed to assess its adaptability to other tumor types with distinct stromal niches.
• Assay Standardization: The complexity of the co-culture system may introduce variability across laboratories, emphasizing the need for clear protocol standardization and reporting.

Nonetheless, the demonstrated physiological relevance and predictive utility of the assembloid model provide a strong rationale for its adoption in preclinical drug screening and personalized medicine applications.

Research Support Resources

To facilitate the modeling of folate metabolism pathways, protection from methotrexate-induced growth suppression, and antifolate drug resistance in complex assembloid systems, researchers may employ high-purity reagents such as Leucovorin Calcium (SKU A2489). This calcium folinate compound is specifically designed for scientific research, offering robust solubility and reliability for cell proliferation and viability assays in physiologically relevant co-culture models. For detailed guidance on integrating Leucovorin Calcium into assembloid workflows or cell proliferation assays, consult both the product information and recent technical reviews on advanced tumor modeling. Solutions should be freshly prepared and stored at -20°C to maintain stability, as per established recommendations.